Pricing Log in Create free account
Saturday 7 November 2026 Export ALGS’s income statement to Excel — free account

Aligos Therapeutics, Inc.

ALGS Healthcare Biotechnology

Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.

Revenue
+287.2%
EPS
+31.3%
Free cash flow
+105.9%

Quarter to September 2026, against a year earlier

4.09 0.42 −9.31%
Market cap
$28.2M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
3/9
Altman Z
−11.00
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 53.64%

Capital & Financial Ratios $m

Size
Market Cap 28.17
Revenue ttm 33.65
Net income ttm (66.28)
Free cash flow ttm (68.37)
Net debt Q (30.42)
Valuation
P/E 0.00
Forward P/E (0.74) (negative: loss-making)
Price / sales 1.27
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.78
Financial health
Current ratio Q 1.77 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (18.98)
Growth
Revenue growth Q +287.18% (above 0%: growing)
Operating income growth Q +22.82% (above 0%: growing)
EPS, this year −167.52% (below 0%: weak)
EPS, next year A +18.01% (at or above 15%: strong)
Revenue, next year A +1,546.39% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −2.18% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.4×, against a ten-year median of −3.0×; over the ten years it ranged from −28.6× in 2025 to 64.8× in 2021.
P/S against its own 10 years 0.08%
10-year low 10-year high
P/B against its own 10 years 90.14%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 136 57 78 —
Receivables — — — —
Inventory — — — —
Other 5 5 5 3
141 62 83 35
2023 2024 2025 Q'26
Payables 3 3 4 3
ST’ Debt — — — —
Other — — — —
24 22 21 20

Compound Annual Growth %

10y 5y 3y
Sales — — (46.03%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (24.62%) (19.83%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −2.44 Actual −2.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −2.09 −1.91 Beat by 0.18
Q1 FY26 −2.29 −2.21 Beat by 0.08
Q2 FY26 −1.41 −0.14 Beat by 1.27
Q3 FY26 −2.44 −2.09 Beat by 0.35
Q4 FY26 −1.91 — Reports 4 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (2.21) (0.14) (2.09) — —
’25 (2.11) (1.53) (3.04) (1.91) (2.45)
’24 (5.50) 0.75 (3.07) (13.08) (20.94)
’23 (13.25) (10.75) (10.25) (5.47) (34.00)
’22 (21.00) (11.75) (11.00) (12.75) (56.25)
’21 (18.50) (19.75) (19.50) (22.25) (80.50)
’20 (189.02) (184.96) (274.91) (27.25) (271.75)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3 28 3 — —
’25 0 1 1 0 2
’24 1 1 1 1 4
’23 3 7 3 3 16
’22 3 4 4 4 14
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) 1 — —
’25 (21) (16) (24) (22) (83)
’24 (23) (19) (20) (18) (81)
’23 (22) (14) (20) (23) (79)
’22 (20) (25) (17) (17) (79)
’21 (30) (23) (25) (37) (116)
’20 (20) (18) (17) (20) (74)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) 1 — —
’25 (21) (16) (25) (22) (83)
’24 (23) (19) (20) (18) (81)
’23 (22) (14) (20) (23) (79)
’22 (21) (25) (17) (17) (80)
’21 (30) (23) (25) (38) (117)
’20 (21) (18) (17) (20) (76)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — 4 14 16 4 2 34 (15.8%) 36 5 52 +187.7%
Gross margin, % — — 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT — — (14) (52) (108) (128) (96) (87) (131) (24) (63) +8.0%
EBT margin, % — — 0.00 0.00 0.00 (2,940.79) (689.87) (559.50) (3,317.62) (1,092.36) (186.65) (1,092.4) pt
Net income — 0 (14) (52) (109) (128) (96) (88) (131) (24) (66) n/m
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.00 2.73 8.14 6.06 0.63 0.22 3.22 n/m
Earnings — — (292.22) (651.02) (271.75) (80.50) (56.25) (34.00) (20.94) (2.45) (6.35) (49.5%)
Cash flow — — (126.81) (582.40) (185.89) (72.55) (46.49) (30.82) (12.89) (8.35) (6.54) (32.2%)
Capex — — (52.75) (34.69) (5.17) (0.56) (0.55) (0.01) (0.02) (0.04) 0.00 (63.7%)
Free cash flow — — (179.56) (617.10) (191.06) (73.11) (47.04) (30.83) (12.91) (8.39) (6.54) (35.4%)
Book value — — (288.22) (808.11) 550.79 115.88 60.84 35.93 (4.62) 5.42 1.08 n/m
Shares, m — — 0 0 0 2 2 3 6 10 10 +114.3%
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — — — 108.53 2.89 5.82 63.27 42.14 1.27 44.5
P/B — — — — — 2.56 0.39 0.98 0.00 1.72 3.78 1.1
EV/Sales — — — — — 64.80 (6.15) (2.91) 48.84 6.54 0.37 22.2
EV/FCF — — — — — (2.42) 1.07 0.57 (2.38) (0.17) (0.18) (0.7)
Cash, $m
Cash, $m Operating cash flow — — (6) (47) (74) (116) (79) (79) (81) (83) (68) +45.2%
Capex — — (3) (3) (2) (1) (1) 0 0 0 0 (22.1%)
Free cash flow — — (9) (50) (76) (117) (80) (79) (81) (83) (68) +38.3%
Balance, $m
Balance, $m Working capital — — 85 106 220 165 100 117 40 62 15 (4.5%)
Net debt — — (91) (118) (244) (191) (126) (136) (57) (78) (30) (2.2%)
Shareholders’ equity — — (14) (65) 220 185 104 92 (29) 54 11 n/m
Returns, %
Returns, % ROA — — (25.87) (41.11) (52.71) (51.26) (50.28) (58.80) (118.41) (30.50) (84.46) (4.6) pt
ROIC — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (400.91) 0.0 pt
ROE — — 35.44 132.92 (139.92) (63.41) (66.55) (89.48) (415.84) (196.92) (159.46) (232.4) pt
People
People Employees — — — 67 74 93 83 66 70 82 — +3.4%
Revenue/emp, $m — — — 0.00 0.00 0.05 0.17 0.24 0.06 0.03 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Aligos Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IRLA IRulya Therapeutics Inc. $29.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
LITS Lite Strategy, Inc. $29.6M — (loss-making) — (loss-making) +647.96% (above 0%: growing) n/m +179.28% (above 0%: growing) 0.00% 0.00% Compare
EDSA Edesa Biotech, Inc. $28.8M — (loss-making) — (loss-making) −99.88% (below 0%: shrinking) n/m −81.24% (below 0%: shrinking) 0.00% 0.00% Compare
ANVS Annovis Bio, Inc. $28.6M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
BCTX BRIACELL THERAP $28.6M — (loss-making) — — n/m +26.73% (above 0%: growing) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $28.2M — (loss-making) — (loss-making) +287.18% (above 0%: growing) n/m +105.91% (above 0%: growing) 100.00% (762.98%)
MGX Metagenomi Therapeutics, Inc. $27.6M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
PLRZ Polyrizon Ltd. $27.5M — — — — −744.51% (below 0%: shrinking) — — Compare
ACET Adicet Bio, Inc. $27.3M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $28.6M — — +274.04% — −27.83% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together 7.80%
Roche Finance Ltd 9.90%
Entities affiliated with Deep Track 9.90%
Entities affiliated with Alyeska Investment Group 9.90%
Entities affiliated with Sio Capital 6.20%
Entities affiliated with Woodline 5.40%
Lawrence M. Blatt, Ph.D., M.B.A. 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aligos Therapeutics, Inc. (ALGS) Latest News

5 Oct

Impact 4 · · GlobeNewswire

12 Aug

Impact 3 ·

13 Jul

Impact 3 ·

6 Jul

Impact 4 · · Stocktwits
Impact 3 ·

13 May

Impact 3 · · GlobeNewswire

7 May

Impact 3 · · GlobeNewswire

17 Apr

Impact 4 · · pharmaceutical-technology.com

16 Apr

Impact 4 · · GlobeNewswire

14 Apr

Impact 4 · · GlobeNewswire

5 Mar

Impact 3 · · GlobeNewswire

23 Feb

Impact 4 · · GlobeNewswire

21 Jan

Impact 4 · · GlobeNewswire

13 Jan

Impact 3 · · GlobeNewswire

7 Jan

Impact 3 · · Simply Wall St.

11 Dec

Impact 4 ·

10 Nov

Impact 4 · · GlobeNewswire

6 Nov

Impact 3 · · GlobeNewswire

16 Oct

Impact 4 · · GlobeNewswireClinical Trials ArenaMT NewswiresBioPharma DiveZacks

14 Oct

Impact 3 · · GlobeNewswire

7 Oct

Impact 3 · · GlobeNewswire

8 Sep

Impact 4 ·

3 Sep

Impact 4 · · GlobeNewswire

21 Aug

Impact 4 ·

20 Aug

Impact 3 · · GlobeNewswire

19 Aug

Impact 4 · · Zacks

14 Aug

Impact 4 · · clinicaltrialsarena.com
Impact 3 · · Zacks

13 Aug

Impact 4 ·

9 Aug

Impact 4 ·
stockrow.com/ALGS · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com